Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Short-term Investments: 2015-2025

Historic Short-term Investments for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $210.0 million.

  • Assembly Biosciences' Short-term Investments rose 215.81% to $210.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.0 million, marking a year-over-year increase of 215.81%. This contributed to the annual value of $73.7 million for FY2024, which is 33.21% down from last year.
  • Assembly Biosciences' Short-term Investments amounted to $210.0 million in Q3 2025, which was up 312.02% from $51.0 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Short-term Investments high stood at $210.0 million for Q3 2025, and its period low was $19.6 million during Q3 2023.
  • In the last 3 years, Assembly Biosciences' Short-term Investments had a median value of $67.6 million in 2025 and averaged $77.3 million.
  • Per our database at Business Quant, Assembly Biosciences' Short-term Investments tumbled by 63.77% in 2023 and then surged by 240.09% in 2024.
  • Over the past 5 years, Assembly Biosciences' Short-term Investments (Quarterly) stood at $101.0 million in 2021, then crashed by 61.20% to $39.2 million in 2022, then spiked by 181.71% to $110.4 million in 2023, then tumbled by 33.21% to $73.7 million in 2024, then spiked by 215.81% to $210.0 million in 2025.
  • Its last three reported values are $210.0 million in Q3 2025, $51.0 million for Q2 2025, and $67.6 million during Q1 2025.